Search
Syncromune's AACR late-breaker of phase 1 data for the SYNC-T immunotherapy drug-device combo in mCRPC
CEO Eamonn Hobbs describes the responses Syncromune is seeing in an early phase 1 prostate cancer study.
Apr 8, 2024
top of page
Search
Follow BiotechTV
Also look for unique social pages for BiotechTV U.
.png){kind=logo}
Sponsor Spotlight
Genezen is a contract development and manufacturing organization (CDMO) with unique technical expertise in lentiviral, retroviral, and adeno-associated viral vectors. Offering process development, GMP viral vector manufacturing, and analytics, we are dedicated to helping you deliver safe, pure, and potent advanced therapies to the patients who need them.
bottom of page